Bromide

Bromide

SCHEMBL1731997

Br.CCc1ccc2c(n1)C(=N)N(CC(=O)c1ccc3c(c1)C(C)(C)C(=O)N3CC(=O)O)C2

nearest known ligand 0.34

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 16/20 0.34
MAPT P10636 3/20 0.33
KDM4E B2RXH2 2/20 0.33
RAB9A P51151 2/20 0.33
NPC1 O15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
LMNA P02545 1/20 0.31
TP53 P04637 1/20 0.31
THRB P10828 1/20 0.31
ALDH1A1 P00352 1/20 0.30
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL1730179 0.89 MAPT (0.35) MAPTKDM4ERAB9ANPC1SMN1; SMN2
Bromide SCHEMBL5490763 0.82 PTGDR2 (0.35) PTGDR2MAPTKDM4ERAB9ANPC1
Bromide SCHEMBL1729683 0.81 KDM4E (0.36) MAPTKDM4ERAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1731333 0.81 KDM4E (0.36) MAPTKDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL27527456 0.81 PTGDR2 (0.35) PTGDR2MAPTKDM4ERAB9ASMN1; SMN2
SCHEMBL27527450 0.81 HSD11B1 (0.36) MAPTKDM4ERAB9ANPC1SMN1; SMN2
Bromide SCHEMBL1729724 0.80 HDAC1 (0.40) MAPTKDM4ERAB9ANPC1SMN1; SMN2
Bromide SCHEMBL5487347 0.79 MAPT (0.37) MAPTKDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL1731338 0.78 MAPT (0.38) MAPTKDM4ERAB9ANPC1SMN1; SMN2
SCHEMBL27527451 0.78 KDM4E (0.32) MAPTKDM4ERAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1391451-B1 2-IMINOPYRROLIDINE DERIVATES EISAI R&D MAN CO LTD (JP) 2011-11-23 EP disclosed
US-7244730-B2 2-iminopyrrolidine derivatives EISAI CO., LTD (JP) 2007-07-17 US disclosed
US-20050245592-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-11-03 US disclosed
US-20050004204-A1 2-Iminopyrrolidine derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-01-06 US disclosed
EP-1391451-A1 2-IMINOPYRROLIDINE DERIVATES Eisai Co., Ltd. (JP) 2004-02-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245592-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 PTGDR2 549/4885MAPT 3483/4885KDM4E 3161/4885
US-20050004204-A1 2-Iminopyrrolidine derivatives H1-2, H1-3, H1-0 PTGDR2 544/4885MAPT 3440/4885KDM4E 3132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.